DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL)
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_119
Abstract: rubicin, epirubicin, vinblastine, etoposide, paclitaxel, and topotecan. RTI‐79's PK characteristics are similar to rifabutin and exhibited no overt toxicity in mice at high doses. RTI‐79 did not exacerbate the known cardiotoxicity associated with doxorubicin as… read more here.
Keywords: rti; novel preclinical; secondary resistance; preclinical models ... See more keywords